Caloca Maria Jose, Wang HongBin, Kazanietz Marcelo G
Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA.
Biochem J. 2003 Oct 15;375(Pt 2):313-21. doi: 10.1042/BJ20030727.
The regulation and function of beta2-chimaerin, a novel receptor for the phorbol ester tumour promoters and the second messenger DAG (diacylglycerol), is largely unknown. As with PKC (protein kinase C) isoenzymes, phorbol esters bind to beta2-chimaerin with high affinity and promote its subcellular distribution. beta2-Chimaerin has GAP (GTPase-activating protein) activity for the small GTP-binding protein Rac1, but for not Cdc42 or RhoA. We show that acidic phospholipids enhanced its catalytic activity markedly in vitro, but the phorbol ester PMA had no effect. beta2-Chimaerin and other chimaerin isoforms decreased cellular levels of Rac-GTP markedly in COS-1 cells and impaired GTP loading on to Rac upon EGF (epidermal growth factor) receptor stimulation. Deletional and mutagenesis analysis determined that the beta2-chimaerin GAP domain is essential for this effect. Interestingly, PMA has a dual effect on Rac-GTP levels in COS-1 cells. PMA increased Rac-GTP levels in the absence of a PKC inhibitor, whereas under conditions in which PKC activity is inhibited, PMA markedly decreased Rac-GTP levels and potentiated the effect of beta2-chimaerin. Chimaerin isoforms co-localize at the plasma membrane with active Rac, and these results were substantiated by co-immunoprecipitation assays. In summary, the novel phorbol ester receptor beta2-chimaerin regulates the activity of the Rac GTPase through its GAP domain, leading to Rac inactivation. These results strongly emphasize the high complexity of DAG signalling due to the activation of PKC-independent pathways, and cast doubts regarding the selectivity of phorbol esters and DAG analogues as selective PKC activators.
β2-嵌合蛋白是佛波酯肿瘤启动子和第二信使二酰基甘油(DAG)的新型受体,其调节作用和功能在很大程度上尚不清楚。与蛋白激酶C(PKC)同工酶一样,佛波酯以高亲和力与β2-嵌合蛋白结合并促进其亚细胞分布。β2-嵌合蛋白对小GTP结合蛋白Rac1具有GTP酶激活蛋白(GAP)活性,但对Cdc42或RhoA没有作用。我们发现酸性磷脂在体外显著增强了其催化活性,但佛波酯PMA没有影响。β2-嵌合蛋白和其他嵌合蛋白同工型在COS-1细胞中显著降低了Rac-GTP的细胞水平,并在表皮生长因子(EGF)受体刺激时损害了Rac上的GTP负载。缺失和诱变分析确定β2-嵌合蛋白的GAP结构域对这种作用至关重要。有趣的是,PMA对COS-1细胞中的Rac-GTP水平有双重作用。在没有PKC抑制剂的情况下,PMA增加了Rac-GTP水平,而在PKC活性受到抑制的条件下,PMA显著降低了Rac-GTP水平并增强了β2-嵌合蛋白的作用。嵌合蛋白同工型与活性Rac共定位于质膜,这些结果通过免疫共沉淀试验得到证实。总之,新型佛波酯受体β2-嵌合蛋白通过其GAP结构域调节Rac GTP酶的活性,导致Rac失活。这些结果强烈强调了由于PKC非依赖性途径的激活,DAG信号传导具有高度复杂性,并对佛波酯和DAG类似物作为选择性PKC激活剂的选择性提出了质疑。